Country |
geographical area |
|
Year |
Ref. |
Age range all adults |
Sample size all adults |
Cannabis (%) |
Cocaine (%) 1a) |
Amphetamines (%) (2) |
Ecstasy (%) |
LSD (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Belgium |
National |
|
2001 |
(5) |
15-64 |
7347 |
2.7 |
|
0.3 |
|
|
Czech Republic |
National |
|
2004 |
(2) |
18-64 |
3526 |
4.8 |
0.0 |
0.2 |
1.1 |
0.1 |
Denmark |
National |
|
2000 |
(3) |
16-64 |
11825 |
2.8 |
0.3 |
0.3 |
0.2 |
0.1 |
Germany |
National |
|
2003 |
(6) |
18-59 |
8061 |
3.4 |
0.4 |
0.4 |
0.2 |
0.1 |
Estonia |
National |
|
2003 |
(2) |
15-64 |
|
1.4 |
0.0 |
0.3 |
0.4 |
0.0 |
Greece |
National (except Aegean and Ionian Islands) |
|
2004 |
(3) |
15-64 |
4351 |
0.9 |
0.0 |
0.0 |
0.0 |
0.0 |
Spain |
National |
|
2003 |
(5) |
15-64 |
12033 |
7.6 |
1.1 |
0.2 |
0.4 |
|
France |
Metropolitan France |
|
2002 |
(5) |
15-64 |
1744 |
|
|
|
|
|
Ireland |
National |
|
2002-03 |
(4) |
15-64 |
4918 |
2.6 |
0.3 |
0.2 |
0.3 |
0.0 |
Italy |
National |
|
2003 |
(2) |
15-54 |
11869 |
4.6 |
0.6 |
0.1 |
0.1 |
0.1 |
Cyprus |
National |
(4) |
2003 |
(1) |
15-65 |
1000 |
9.0 |
0.7 |
|
1.6 |
|
Latvia |
National |
|
2003 |
(1) |
15-64 |
4534 |
1.8 |
0.1 |
0.5 |
0.3 |
0.3 |
Lithuania |
National |
|
2004 |
(1) |
15-64 |
4207 |
0.7 |
0.1 |
0.1 |
0.2 |
0.0 |
Luxembourg |
National |
|
1998 |
(1) |
15-64 |
|
4.0 |
0.2 |
|
0.0 |
0.0 |
Hungary |
National |
|
2003 |
(2) |
18-54 |
|
1.4 |
0.2 |
0.4 |
0.4 |
0.2 |
Malta |
National |
|
2001 |
(1) |
18-64 |
|
0.5 |
0.1 |
0.0 |
0.2 |
0.0 |
Netherlands |
National |
|
2001 |
(2) |
15-64 |
14045 |
3.7 |
0.5 |
0.3 |
0.6 |
0.0 |
Austria |
National |
|
2004 |
(1) |
15-64 |
3980 |
3.8 |
0.4 |
0.4 |
0.4 |
0.1 |
Poland |
National |
|
2002 |
(1) |
16-64 |
|
1.3 |
0.1 |
0.2 |
0.2 |
0.0 |
Portugal |
National |
|
2001 |
(1) |
15-64 |
14186 |
2.4 |
0.1 |
0.1 |
0.2 |
0.0 |
Slovakia |
National |
|
2004 |
(2) |
15-64 |
1315 |
1.7 |
0.1 |
0.0 |
0.4 |
|
Finland |
National |
|
2004 |
(6) |
15-64 |
2352 |
1.6 |
0.0 |
0.2 |
0.2 |
0.1 |
Sweden |
National |
|
2005 |
(6) |
16-64 |
30538 |
0.8 |
|
|
|
|
United Kingdom |
England and Wales |
|
2004-05 |
(8) |
16-59 |
28509 |
5.6 |
0.9 |
0.5 |
0.7 |
0.0 |
United Kingdom |
Northern Ireland |
|
2002-03 |
(9) |
15-64 |
3516 |
2.9 |
0.1 |
0.2 |
0.5 |
0.0 |
United Kingdom |
Scotland |
|
2003 |
(10) |
16-64 |
3506 |
4.2 |
0.4 |
0.3 |
0.6 |
0.0 |
United Kingdom |
United Kingdom |
|
2004 |
(11) |
|
35707 |
6.2 |
1.0 |
0.5 |
0.9 |
0.1 |
Bulgaria |
National |
|
2005 |
(1) |
18-60 |
1036 |
0.8 |
0.2 |
0.2 |
0.5 |
0.2 |
Romania |
National |
|
2004 |
(1) |
15-64 |
|
|
|
|
|
|
Norway |
National |
|
2004 |
(2) |
15-64 |
2669 |
2.2 |
0.3 |
0.2 |
0.1 |
0.0 |
Notes: (1) Cocaine in any form. (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamines and ecstasy. (3) For Spain: ecstasy and other synthetic drugs. (4) Results of this survey should be viewed with caution due to important discrepancies with previous surveys and school surveys results. A new survey with a bigger sample was conducted in 2005. This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey. In surveys with small sample sizes results should be interpreted with caution. Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15 to 64, young adults: 15 to 34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions. See also 'General notes for interpreting data' on the Explanatory notes and help page. Sources: See Table GPS-0. | |||||||||||